Liu L, Hofstetter WL, Rashid A, Swisher SG , Correa AM, Ajani JA, Hamilton SR, Wu TT
Ethics declarations Ethical approval and consent to participate Not Applicable
The brand's FAQ describes it as generally safe for daily use and recommends rotating the application site with each patch replacement
If you are approaching the end of the first month and still not feeling any appetite changes, our guide on 4 weeks on semaglutide with no weight loss covers the troubleshooting steps
J Endocr Soc 5(9):bvab118 Doggrell SA (2023) Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist, a step forward in the treatment of diabetes and obesity
Patients should be empowered to recognise warning signs and maintain open communication with their healthcare team to ensure both the benefits of treatment and electrolyte homeostasis are optimised throughout the course of therapy